Heteroaryl Beta-Hydroxyethylamines for Insulin-Independent Glucose Uptake

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hyperglycemia and type 2 diabetes, particularly those involving insulin receptor mutations, are insufficiently effective and come with significant side effects, necessitating the exploration of novel insulin-independent mechanisms for glucose uptake in skeletal muscle cells.

Innovation Solution

Development of heteroaryl substituted β-hydroxyethylamines that act as agonists at the β2-adrenergic receptor to increase glucose uptake in skeletal muscle without significant cAMP release, thereby reducing common side effects associated with traditional β2-adrenergic agonists.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional β2-adrenergic agonists are used to increase glucose uptake in skeletal muscle, then glucose uptake is improved, but cAMP-mediated side effects worsen

Engineering Contradiction:

Improveglucose uptakeVSAvoidcAMP-mediated side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the molecular structure of β2-adrenergic agonists by introducing heteroaryl substituents at specific positions (e.g., position 1 of the ethylamine chain), changing the pharmacological parameters of the drug to achieve selective activation of β2-receptors with reduced cAMP signaling, thereby improving glucose uptake while minimizing side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs heteroaryl substituted β-hydroxyethylamines as intermediary compounds that act as selective β2-adrenergic agonists, mediating the glucose uptake effect through alternative signaling pathways that do not heavily rely on cAMP, thus reducing harmful side effects while maintaining therapeutic benefit

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If insulin receptor sensitivity drugs are used to treat hyperglycemia, then glucose homeostasis is improved, but treatment effectiveness worsens in patients with insulin receptor mutations

Engineering Contradiction:

Improveglucose homeostasisVSAvoidtreatment effectiveness

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent extracts the therapeutic mechanism from the insulin signaling pathway and activates it through a different route - direct stimulation of β2-adrenergic receptors on skeletal muscle cells, which independently increase glucose uptake through AMPK activation, thereby bypassing the defective insulin receptor completely

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces the insulin-based signaling mechanism with a catecholamine-based β2-adrenergic signaling mechanism, substituting one biological pathway for another that is functional in patients with insulin receptor mutations, thereby restoring glucose homeostasis without relying on the defective insulin pathway

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Productivity

If current diabetes treatments are used, then glucose control is improved, but side effects worsen

Engineering Contradiction:

Improveglucose controlVSAvoidside effects

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent achieves local quality by selecting β2-adrenergic receptors specifically expressed in skeletal muscle tissue, directing the therapeutic effect to the relevant site for glucose uptake while avoiding systemic effects associated with other receptor subtypes, thereby improving glucose control with reduced side effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent converts the typically harmful cAMP-mediated signaling into a beneficial pathway by using heteroaryl substituted agonists that activate β2-receptors through alternative mechanisms, turning what would be a source of side effects into a therapeutic advantage for glucose uptake without the usual cardiovascular and metabolic adverse effects

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds effectively promote glucose uptake in skeletal muscle, offering a promising treatment for hyperglycemia and type 2 diabetes with a favorable side-effect profile by activating the β2-adrenergic receptor without the typical cAMP-mediated side effects.

Implementation Method 1

Development of heteroaryl substituted β-hydroxyethylamines that act as agonists at the β2-adrenergic receptor to increase glucose uptake in skeletal muscle

Methodology Applied

Scientific Effectβ2-adrenergic receptor activation:

Implementation Method 2

These compounds effectively promote glucose uptake in skeletal muscle, offering a promising treatment forhyperglycemia and type 2 diabetes with a favorable side-effect profile by activating the β2-adrenergic receptor without the typical cAMP-mediated side effects

Methodology Applied

Scientific EffectcAMP-mediated signaling:

Data Source

PatentUS20240398770A1Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

Publication Date: 2024.12.05 ATROGI

AI summary

There is herein provided a compound of formula Ior a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.